Table 1.
Oncogenic pathwaya | PD-Ll-positive HCC (n = 40) | PD-Ll-negative HCC (n = 114) | p valueb |
---|---|---|---|
β-catenin | |||
Alteration (+) | 5 | 34 | 0.0302 |
Alteration (−) | 35 | 80 | |
p53/cell cycle control | |||
Alteration (+) | 15 | 37 | 0.5617 |
Alteration (−) | 25 | 77 | |
Chromatin remodeling | |||
Alteration (+) | 7 | 17 | 0.6979 |
Alteration (−) | 33 | 97 | |
Epigenetic regulator | |||
Alteration (+) | 5 | 19 | 0.5319 |
Alteration (−) | 35 | 95 | |
PI3K-Akt | |||
Alteration (+) | 8 | 8 | 0.0206 |
Alteration (−) | 32 | 106 | |
Oxidative and ER stress | |||
Alteration (+) | 3 | 12 | 0.5786 |
Alteration (−) | 37 | 102 | |
DNA repair | |||
Alteration (+) | 3 | 11 | 0.6842 |
Alteration (−) | 37 | 103 | |
TERT promoter | |||
Alteration (+) | 26 | 73 | 0.9127 |
Alteration (−) | 14 | 41 |
Bold type denotes significance.
The presence or absence of alteration in the oncogenic pathway was determined based on the mutations, homozygous deletion, and/or amplification of cancer-related genes in each pathway.
Pearson's χ2 test.